Gracell Biotechnologies Co. Ltd., of Shanghai, said it has developed FasT CAR-T, a platform that shortens the manufacturing time of CAR T treatments from two weeks to one day. FasT CAR-T also lowers manufacturing costs to a fraction of previous CAR T therapies, while showing higher potency of CD19-directed FasT CAR-T in B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma, in vitro and in vivo. A first-in-human trial is ongoing.